AuthenTicity of Point of Care Urine samplEs Using Oral fluoreScein Sodium in adulTs With substancE Use Disorder
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 114
- 主要终点
- Detection
研究概览
简要总结
The purpose of this phase III, randomized, double-blind, placebo-controlled study is to confirm the authenticity of point-of-care urine samples in adult persons with substance use disorder using fluorescein sodium as a marker. Eligible persons will, drink a sample of Gatorade™ which includes either, 100 mg fluorescein sodium, or not, followed by 500 mL of water. Fifteen minutes after consuming the Gatorade™, participants will provide a mid-stream urine sample (at least 10 mL urine is required) for examination of fluorescence (in a single-blinded manner) using a Qubit™ fluorometer.
详细描述
One hundred fourteen eligible persons will be randomized. One hour after completely emptying their bladders, in a blinded manner, half will receive Gatorade and the other half will receive Gatorade with 100 mg of fluorescein. All will then drink 500 ml of water and 15 minutes later they will provide urine samples. A solution of sodium bicarbonate will be added to the samples and blinded observers will then examine all of the samples for fluorescence using a Qbit fluorometer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •• Written informed consent, obtained from the person or legally acceptable representative, before any study-related procedure is performed. Adults aged between 18 and 65 years, inclusive, at the time of signing the informed consent form.
- •A documented current substance use disorder, including but not limited to alcohol, cocaine, and/or opioid.
- •Female participants must be: Not women of childbearing potential (WOCBP), i.e., postmenopausal and/or surgically sterile, OR: WOCBP who agree to use a contraceptive method that is highly effective (based on the investigator's judgment) for 28 days before and after study product administration.
- •Male participants must agree to use effective birth control methods and must not donate sperm until 2 weeks after study product administration.
- •Must agree not to be a gamete donor from Screening until 28 days after the follow-up telephone call.
- •Willing and able to comply with the study instructions and attend all scheduled study visits.
排除标准
- •Life expectancy less than 5 years.
- •Women who are pregnant or are breast-feeding.
- •Known cirrhosis.
- •Diagnosis of Gilbert's syndrome.
- •Heart failure, classified as being in New York Heart Association Class II-IV at Screening.
- •Known allergy to fluorescein, Gatorade™, or any of their excipients.
- •Estimated glomerular filtration rate <30 mL/min/1.73m2 using the Cockroft-Gault method at Screening.
- •Hemoglobin <120 g/L at Screening.
- •Diagnosis of sickle cell anemia or sickle cell trait.
- •Any major episode of infection requiring hospitalization and/or treatment with intravenous antiinfective agents during the 2 months prior to Screening.
- •Use of fluorescein for medical imaging (eg, angiogram, corneal staining) in the 3 days prior to the Randomization Visit. UP
- •In the opinion of the investigator, any other condition that would preclude participation in the study.
研究组 & 干预措施
Fluorescein
Ingestion of 100 mg of fluorescein with 250 ml Gatorade tm
干预措施: Fluorescein (Drug)
placebo
ingestion of 250 ml Gatorade tm without fluorescein
干预措施: placebo (Other)
结局指标
主要结局
Detection
时间窗: 15 minutes post ingestion
Presence of fluorescence
次要结局
未报告次要终点